Low doses of 15d-PGJ2 induce osteoblast activity in a PPAR-gamma independent manner

International Immunopharmacology

Volumn 16, Issue 2, 2013, Pages 131-138

  Napimoga, Marcelo Henrique ^a   Demasi, Ana Paula Dias ^a   Bossonaro, Jeruza P ^a   De Araújo, Vera Cavalcanti ^a   Clemente Napimoga, Juliana Trindade ^b   Martinez, Elizabeth Ferreira ^a  

^a SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

15d PGJ2; Bone; Inflammation; Osteoblast; PPAR gamma

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; COLLAGEN TYPE 1; HISTONE DEACETYLASE; HISTONE DEACETYLASE 9C; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR RUNX; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN TYPE I; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HISTONE DEACETYLASES; MICE; OSTEOBLASTS; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; PPAR GAMMA; PROSTAGLANDIN D2; RANK LIGAND; REPRESSOR PROTEINS;

EID: 84877601341     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.03.035     Document Type: Article

References (38)

1. M. Kawai, K.M. Sousa, O.A. Macdougald, and C.J. Rosen The many facets of PPARgamma: novel insights for the skeleton Am J Physiol Endocrinol Metab 299 2010 E3 E9
2. C. Terrie-Anne, J. Back, F. Elefteriou, G. Karsenty, P. Kastner, and S. Chan Enhanced bone formation in lipodystrophic PPARγhyp/hyp mice relocates haematopoiesis to the spleen EMBO Rep 5 2004 1007 1012 (Pubitemid 39534460)
3. B. Lecka-Czernik, and L.J. Suva Resolving the Two «Bony» Faces of PPAR-gamma PPAR Res 2006 2006 27489
4. A. Grey, M. Bolland, G. Gamble, D. Wattie, A. Horne, and J. Davidson The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 92 2007 1305 1310 (Pubitemid 46556402)
5. O.P. Lazarenko, S.O. Rzonca, W.R. Hogue, F.L. Swain, L.J. Suva, and B. Lecka-Czernik Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone Endocrinology 148 2007 2669 2680 (Pubitemid 46984815)
6. A. Grey Skeletal consequences of thiazolidinedione therapy Osteoporos Int 19 2008 129 137
7. B. Lecka-Czernik, E.J. Moerman, D.F. Grant, J.M. Lehmann, S.C. Manolagas, and R.L. Jilka Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation Endocrinology 143 2002 2376 2384 (Pubitemid 34521584)
8. S. Eligini, C. Banfi, M. Brambilla, M. Camera, S.S. Barbieri, and F. Poma 15-deoxy-D12,14-prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade Thromb Haemost 88 2002 524 532 (Pubitemid 35021614)
9. M.H. Napimoga, S.M. Vieira, D. Dal-Secco, A. Freitas, F.O. Souto, and F.L. Mestriner Peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-Delta12,14-prostaglandin J2, reduces neutrophil migration via a nitric oxide pathway J Immunol 180 2008 609 617
10. C. Alves, N. de Melo, L. Fraceto, D. de Araújo, and M. Napimoga Effects of 15d-PGJ-loaded poly(D, L-lactide-co-glycolide) nanocapsules on inflammation Br J Pharmacol 162 2011 623 632
11. T.S. Farnesi-de-Assunção, C.F. Alves, V. Carregaro, J.R. de Oliveira, C.A. da Silva, and A.B. Cheraim PPAR-γ agonists, mainly 15d-PGJ(2), reduce eosinophil recruitment following allergen challenge Cell Immunol 273 2012 23 29
12. M.H. Napimoga, C.A. da Silva, V. Carregaro, T.S. Farnesi-de- Assunção, P.M. Duarte, and L.F. Fraceto Exogenous administration of 15d-PGJ2-loaded nanocapsules inhibits bone resorption in a mouse periodontitis model J Immunol 189 2012 1043 1052
13. Y.-J. Surh, H.K. Na, J.M. Park, H.N. Lee, W. Kim, and I.S. Yoon 15-Deoxy-D12,14-prostaglandin J2, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling Biochem Pharmacol 82 2011 1335 1351
14. D.S. Straus, G. Pascual, M. Li, J.S. Welch, M. Ricote, and C.H. Hsiang 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway Proc Natl Acad Sci U S A 97 2000 4844 4849 (Pubitemid 30238645)
15. W.K. Jung, I.S. Park, S.J. Park, S.S. Yea, Y.H. Choi, and S. Oh The 15-deoxy-D12,14-prostaglandin J2 inhibits LPS-stimulated AKT and NF-kB activation and suppresses interleukin-6 in osteoblast-like cells MC3T3E-1 Life Sci 85 2009 46 53
16. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R.M. Evans PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nat Med 7 2001 48 52 (Pubitemid 32095641)
17. T. Akune, S. Ohba, S. Kamekura, M. Yamaguchi, U.I. Chung, and N. Kubota PPAR insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors J Clin Invest 113 2004 846 855 (Pubitemid 38544143)
18. A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, and R.L. Jilka Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 146 2005 1226 1235 (Pubitemid 40289310)
19. M. Collin, M. Abdelrahman, and C. Thiemermann Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock Eur J Pharmacol 486 2004 233 235 (Pubitemid 38224534)
20. M. Collin, O. Murch, and C. Thiemermann Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia Crit Care Med 34 2006 1131 1138
21. D.W. Gilroy, P.R. Colville-Nash, D. Willis, J. Chivers, M.J. Paul-Clark, and D.A. Willoughby Inducible cyclooxygenase may have anti-inflammatory properties Nat Med 5 1999 698 701 (Pubitemid 29289435)
22. H. Li, and C.D. Pauza Effects of 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) and rosiglitazone on human gammadelta2 T cells PLoS One 4 2009 e7726
23. J.T. Clemente-Napimoga, J.A. Moreira, R. Grillo, N.F. de Melo, L.F. Fraceto, and M.H. Napimoga 15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties into rat temporomandibular hypernociception Life Sci 90 2012 944 999
24. J.Y. Choi, B.H. Lee, K.B. Song, R.W. Park, I.S. Kim, and K.Y. Sohn Expression patterns of bone-related proteins during osteoblastic differentiation in MC3T3 E1 cells J Cell Biol 61 1996 609 618 (Pubitemid 26240139)
25. R.T. Franceschi, and B.S. Iyer Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells J Bone Miner Res 7 1992 235 246
26. R. Zohar, S. Cheifetz, C.A. McCulloch, and J. Sodek Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration Eur J Oral Sci 106 1998 401 407 (Pubitemid 128737256)
27. D. Wang, K. Christensen, K. Chawla, G. Xiao, P.H. Krebsbach, and R.T. Franceschi Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential J Bone Miner Res 14 1999 893 903 (Pubitemid 29262883)
28. K. Ibaraki, J.D. Termine, S.W. Whitson, and M.F. Young Bone matrix mRNA expression in differentiating fetal bovine osteoblasts J Bone Miner Res 7 1992 743 754
29. Y. Luan, C.A. Praul, and C.V. Gay Confocal imaging and timing of secretion of matrix proteins by osteoblasts derived from avian long bone Comp Biochem Physiol A Mol Integr Physiol 126 2000 213 221 (Pubitemid 30628915)
30. P.T. De Oliveira, S.F. Zalzal, K. Irie, and A. Nanci Early expression of bone matrix proteins in osteogenic cell cultures J Histochem Cytochem 51 2003 633 641 (Pubitemid 36520619)
31. T. Shibata, M. Kondo, T. Osawa, N. Shibata, M. Kobayashi, and K. Uchida 15-deoxy-D12,14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes J Biol Chem 277 2002 10459 10466 (Pubitemid 34968167)
32. 2, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling Biochem Pharmacol 82 2011 1335 1351
33. E.H. Kim, and Y.J. Surh 15-deoxy-D12,14-prostaglandin J2 as a potential endogenous regulator of redox-sensitive transcription factors Biochem Pharmacol 72 2006 1516 1528
34. T. Jenuwein, and C.D. Allis Translating the histone code Science 293 2001 1074 1080 (Pubitemid 32758077)
35. K. Ito, S. Lim, G. Caramori, B. Cosio, K.F. Chung, and I.M. Adcock A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression Proc Natl Acad Sci U S A 99 2002 8921 8926 (Pubitemid 34693659)
36. S. Bai, and X. Cao A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor- signaling J Biol Chem 277 2002 4176 4182 (Pubitemid 34968679)
37. Y.H. Chen, F.L. Yeh, S.P. Yeh, H.T. Ma, S.C. Hung, and L.Y. Li Myocyte enhancer factor-2 interacting transcriptional repressor (MITR) is a switch that promotes osteogenesis and inhibits adipogenesis of mesenchymal stem cells by inactivating peroxisome proliferator-activated receptor gamma-2 J Biol Chem 286 2011 10671 10680
38. K. Farrajota, S. Cheng, J. Martel-Pelletier, H. Afif, J.P. Pelletier, and X. Li Inhibition of interleukin-1beta-induced cyclooxygenase 2 expression in human synovial fibroblasts by 15-deoxy-Delta12,14-prostaglandin J2 through a histone deacetylase-independent mechanism Arthritis Rheum 52 2005 94 104 (Pubitemid 40129237)